Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
519 Leser
Artikel bewerten:
(2)

Caerus Us 1 Inc. (dba Citeline): Introducing Citeline's Sitetrove Diversity Module, Combining Robust Clinical Investigator and Site Intelligence With Patient Demographics to Support the Diversification of Clinical Trials

NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- With new Food and Drug Administration (FDA) guidance, study sponsors are no longer viewing clinical trial diversity as "nice to have" but as a "must have." Citeline's new Sitetrove Diversity Module marries robust site and investigator intelligence with patient age, race and gender data, enabling data-driven decision making to support the diversification of clinical trials.

The Diversity Module includes patient racial demographics from medical claims along with investigator gender data from the Centers for Medicare & Medicaid Services (CMS). The patient data are broken down by Asian, Black/African American, Hispanic, White and unknown. Sponsors will now be able to identify expert clinical investigators with relevant trial experience and who have access to diverse patient populations in one continuous workflow.

Enacted in December 2022, the U.S. 2023 omnibus spending bill requires diversity action plans for Phase 3 or pivotal clinical trials used by the FDA to determine the safety and efficacy of drugs. It reflects a concerted effort to reverse a growing trend: lack of diversity in clinical trials. In fact, according to a recent study, U.S. clinical trial diversity has dropped to its lowest level of the decade.

Citeline's Sitetrove Diversity Module is designed to support Sponsors' activities surrounding these imminent requirements, including feasibility, planning and investigator/site selection - all of which drive recruitment strategy. Beyond regulatory requirements, sponsors can leverage this demographic data to demonstrate a broader commitment to clinical trial diversity, equity, and inclusion.

"Clinical trial sponsors now have specific U.S. legal obligations, in addition to ethical ones, for improving diversity in their research studies," said Dave Laky, General Manager of Clinical & Regulatory at Citeline. "While sponsors may worry about the challenges of recruiting underserved communities, pinpointing where diverse patients are being treated is a great first step towards enrolling these individuals. Our new Diversity Module is one example of how Citeline is actively investing in the expansion of our patient and provider demographic data to enable data-driven decision making."

Citeline is also developing a Diversity API, scheduled for release later this quarter, that will allow users to analyze ICD10-specific patient counts by age, race and gender, for U.S. clinical investigators and organizations. Additional developments are planned for the Diversity Module in the coming months, including enhanced visualizations, enriched datasets, organization-level diversity insights, and patient landscapes outside the U.S.

Learn more about Citeline's Sitetrove.

About Citeline
Citeline, a Norstellacompany, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.

Citeline's global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world's most trusted health science partners, visit Citeline.

Citeline PR contact:
Diffusion PR for Citeline
citeline@diffusionpr.com
(213) 318-4500


© 2023 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.